To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Arms Length Body Publication (Published)
NICE

Oct. 21 2025

Source Page: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
Publication Type: Expected publication
Document: TA909 Final stakeholder list (PDF 184 KB) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 21 2025

Source Page: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
Publication Type: Expected publication
Document: Equality impact assessment (guidance development) (PDF 124 KB) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 21 2025

Source Page: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
Publication Type: Expected publication
Document: TA909 DG Committee papers (PDF 6.88 MB) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 21 2025

Source Page: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
Publication Type: Supporting evidence
Document: Final draft guidance committee papers (PDF 2.2 MB) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 21 2025

Source Page: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
Publication Type: Summary PDF
Document: Download (PDF) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 21 2025

Source Page: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
Publication Type: Summary PDF
Document: Download guidance (PDF) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 21 2025

Source Page: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
Publication Type: Resource impact
Document: Resource impact template (Excel 2.34 MB) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 21 2025

Source Page: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
Publication Type: Supporting evidence
Document: Draft guidance consultation committee papers (PDF 7.02 MB) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 21 2025

Source Page: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
Publication Type: Expected publication
Document: TA909 Draft consultation document (downloadable version) (PDF 382 KB) (webpage)
Arms Length Body Publication (Guidance)
NHS England

Oct. 20 2025

Source Page: Research matters: enabling and sustaining a research-positive culture for nurses, midwives and allied health professionals
Document: Research matters: enabling and sustaining a research-positive culture for nurses, midwives and allied health professionals (webpage)